当前位置: 首页 > 详情页

Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Xuanwu Hosp, Natl Ctr Neurol Disorders, Dept Neurol, Beijing, Peoples R China [2]Peoples Liberat Army Gen Hosp, Med Ctr 1, Sr Dept Neurol, Beijing, Peoples R China [3]Shandong Univ, Qilu Hosp, Res Inst Neuromuscular & Neurodegenerat Dis, Cheeloo Coll Med,Dept Neurol, Jinan, Peoples R China [4]Zhengzhou First Peoples Hosp, Dept Neurol, Zhengzhou, Peoples R China [5]Peoples Hosp Shijiazhuang Hebei Med, Ctr Treatment Myasthenia Gravis, Shijiazhuang, Peoples R China
出处:
ISSN:

关键词: Generalized myasthenia gravis Efgartigimod Treatment response Predictors Retrospective study

摘要:
Background and PurposeEfgartigimod has demonstrated efficacy in generalized myasthenia gravis (gMG) in both clinical trials and real-world studies. However, factors influencing early response have been less reported. This study aimed to evaluate the efficacy of efgartigimod in a multicenter gMG cohort and to identify the clinical factors associated with early therapeutic response.MethodsThis multicenter, real-world, retrospective, observational study included 115 gMG patients administered efgartigimod across four myasthenia gravis (MG) centers. Responders were defined as patients with a >= 2-point Myasthenia Gravis Activities of Daily Living (MG-ADL) or >= 3-point Quantitative Myasthenia Gravis Score (QMG) score reduction, while early responders were those achieving score reductions after the first infusion. Subgroup analyses were conducted based on immunosuppressant (IST) use. Logistic regression analysis was performed to identify factors associated with response to first efgartigimod infusion according to MG-ADL or QMG scores reduction. Variables were compared between responders and non-responders to identify early response factors.ResultsAfter the first infusion, 72.5% of patients achieved improvement in MG-ADL and 60.5% in QMG, with these rates increasing to 93.3% and 87.5% respectively by the fourth infusion. Efgartigimod demonstrated the most significant improvement in bulbar, limb, and ocular symptoms; however, there was no statistically significant improvement in respiratory symptoms occurred during the initial 4-week treatment period. Multivariate logistic analysis showed that short disease duration and high MG-ADL bulbar score at baseline indicated early response. High QMG bulbar score at baseline also indicated early response. Efficacy was independent of IST use. No patients discontinued treatment due to severe adverse events; minor side effects were not recorded.ConclusionsEfgartigimod demonstrated robust efficacy in gMG patients. Early response was linked to shorter disease duration and severe bulbar symptoms, which promotes the identification of patients who are likely to benefit quickly from efgartigimod.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 临床神经病学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 临床神经病学
JCR分区:
出版当年[2023]版:
Q1 CLINICAL NEUROLOGY
最新[2024]版:
Q1 CLINICAL NEUROLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Capital Med Univ, Xuanwu Hosp, Natl Ctr Neurol Disorders, Dept Neurol, Beijing, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:18234 今日访问量:0 总访问量:998 更新日期:2025-10-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院